BioVie Inc. (BIVI)
Oxford Ledge is still expanding full research coverage of BIVI. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
BioVie develops bezisterim, an anti-inflammatory drug candidate, for neurodegenerative diseases and Long COVID.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-05-11
- 10-Q Quarterly financial report (unaudited) 2026-02-06
- 8-K Departure/election of directors or officers; Financial statements and exhibits 2025-11-13
- 8-K Shareholder vote results 2025-11-12
- 10-Q Quarterly financial report (unaudited) 2025-11-10
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for BIVI. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open BIVI in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.